Seventeen Alpha-hydroxylase Deficiency  by Wong, Siew-Lee et al.
177J Formos Med Assoc | 2006 • Vol 105 • No 2
17_-hydroxylase deficiency
Seventeen _-hydroxylase deficiency (17OHD) is a rare form of congenital adrenal hyperplasia in which
defects in the biosynthesis of cortisol and sex steroid result in mineralocorticoid excess, hypokalemic
hypertension and sexual abnormalities such as pseudohermaphroditism in males, and sexual infantilism
in females. The disease is inherited in an autosomal recessive pattern, and is caused by mutations in the gene
encoding cytochrome P450c17 (CYP17), which is the single polypeptide that mediates both 17_-hydroxylase
and 17,20-lyase activities. We report the case of a 15-year-old patient with 17OHD who had a female phenotype
but male karyotype (46,XY). The diagnosis was made based on classical clinical features, biochemical data
and molecular genetic study. Two mutations were identified by polymerase chain reaction amplification and
sequencing, including a S106P point mutation in exon 2 and a 9-bp (GACTCTTTC) deletion from nucleotide
position 1519 in exon 8 of CYP17. The first of these mutations was found in the father and the second in the
mother, and both have been previously reported in Asia. The patient’s hypertension and hypokalemia resolved
after glucocorticoid replacement and treatment with potassium-sparing diuretics. Sex hormone replacement
was prescribed for induction of sexual development and reduction of the final height. Prophylactic
gonadectomy was scheduled. In summary, 17OHD should be suspected in patients with hypokalemic
hypertension and lack of secondary sexual development so that appropriate therapy can be implemented.
[J Formos Med Assoc 2006;105(2):177–181]
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Seventeen _-hydroxylase deficiency (17OHD) is
a rare autosomal recessive disorder with an esti-
mated incidence of approximately 1 in 50,000 in-
dividuals.1 It was initially described in 1966 by
Biglieri et al in a genotypical female, whose con-
dition was characterized by hypertension, hypoka-
lemia and lack of puberty.2 In 1970, New reported
an affected genotypical male presenting with male
pseudohermaphroditism.3 The disease affects both
adrenal and gonadal glands.4 Genetic mutations
have been demonstrated in the gene encoding
cytochrome P450c17 (CYP17) on chromosome
10q24-q25, causing 17_-hydroxylase/17,20-lyase
deficiency.5,6 The consequent defects in the synthe-
sis of cortisol and compensatory hypersecretion
of adrenocorticotropic hormone (ACTH) stimulate
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the synthesis of a large quantity of 11-deoxycorti-
costerone (DOC) and corticosterone by the zona
fasciculata. High concentrations of DOC, which is
a potent mineralocorticoid, lead to hypertension,
hypokalemia, a suppressed renin-angiotensin
system, and low plasma aldosterone concentration.
However, normal or high aldosterone levels have
been reported in several cases. In gonads, the ab-
sence of 17,20-lyase activity prohibits the synthe-
sis of androgens, which causes pseudohermaphro-
ditism in males and sexual infantilism with pri-
mary hypogonadism in females.7
To date, more than 130 cases of 17OHD7 and
nearly 50 different mutations8 in CYP17 have been
reported, although they are more prevalent in cer-
tain ethnic groups, particularly in Brazilians and
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male external genitalia with a normal hymen.
Breast and pubic hair development were Tanner
stage I. She was 161 cm tall and weighed 48 kg.
Her blood pressure was 163/81 mmHg at the first
visit. Laboratory evaluation (Table) revealed hy-
pokalemia (2.8 mmol/L) without alkalosis. Plas-
ma 17-hydroxyprogesterone (0.39 mIU/mL; nor-
mal range, 0.49–2.3 mIU/mL) and cortisol (2.92
+g/dL; normal range, A.M.: 5–25 +g/dL, P.M.: half
of A.M.) were decreased, and progesterone (1.7
ng/mL; normal range, < 0.6 ng/mL) was increased.
Plasma ACTH (210 pg/mL; normal range, ND–46
pg/mL) was markedly elevated. Plasma renin ac-
tivity was normal, but aldosterone level (400
pg/dL; normal range, 37.5–240 pg/dL) was high.
Follicle stimulating hormone (70.2 mIU/mL) and
luteinizing hormone (30.9 mIU/mL) were elevat-
ed and at adult castrate levels. Testosterone and
estradiol levels were undetectable. Pelvic ultrason-
ogram revealed neither uterus nor ovaries, and
testes were undetectable. Karyotype analysis was
46,XY. Bone age was 8.5 years for males and adre-
nal magnetic resonance imaging showed no abnor-
mal findings.
In order to identify genetic mutations, poly-
merase chain reaction (PCR) amplification and
Japanese.8,9 Here, we describe the clinical, hor-
monal and molecular genetic characteristics of a
Taiwanese patient with 17OHD.
Case Report
This 15-year-old patient was an apparently normal
female born to non-consanguineous parents. She
weighed 3 kg when she was uneventfully delivered
at full term, and had achieved normal develop-
mental milestones. She had a history of hyper-
tension, found incidentally during school screen-
ing 2 years previously, which did not respond to
treatment with antihypertensive agent. There
was no family history of chronic illness, including
hypertension. The father and mother were 168 cm
and 164 cm tall, respectively, and had normal
pubertal and reproductive histories. She had an
older sister with normal female phenotype and
secondary sexual development with regular
menstruation. The patient sought medical atten-
tion for sexual infantilism and uncontrollable
hypertension. Meanwhile, she was depressed and
suicidal as a result of her symptoms.
On physical examination, she had normal fe-
Table.   Laboratory data before and after glucocorticoid replacement
Variable Normal range
Months of treatment
0 1  2 6 7
ACTH ND–46 pg/mL 210 16 – 77.1 –
Aldosterone 37.5–240 pg/dL 400 136 137 264 233
Renin 3.6–63.7 pg/dL (standing) 16.2 5.92 19.16 6.94 –
Cortisol A.M.: 5–25 +g/dL 2.92 – – – –
P.M.: half of A.M.
17-OH PGTR 0.49–2.3 mIU/mL 0.39 – – – –
Progesterone M < 0.6 ng/mL – 1.7 – 4.2 –
FSH M: 1.5–14 mIU/mL 70.2 – – – –
LH M: 1.4–7.7 mIU/mL 30.9 – – – –
Estradiol M < 56 pg/mL < 20 – – – –
Testosterone M: 2.7–17.3 ng/mL (20–40 yr) < 0.2 – – – –
Sodium 137–153 mmol/L 146 142 140 142 –
Potassium 3.5–5.3 mmol/L 2.8 3.4 3.8 – 3.5
pH/HCO
3
– – 7.39/23.5 – – –
ACTH = adrenocorticotropic hormone; 17-OH PGTR = 17-hydroxyprogesterone; FSH = follicle stimulating hormone; LH = luteinizing
hormone; M = male.
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sequencing were performed after genomic DNA
was extracted from peripheral blood. Exons 1–8
of the CYP17 gene were individually amplified
by PCR with AmpliTaq Gold (Applied Biosystems,
Foster City, CA, USA) as described previously.10
Two different mutations were identified, includ-
ing a point mutation S106P in exon 2 and a 9-bp
(GACTCTTTC) deletion from nucleotide position
1519 in exon 8 of P450c17 (Figure). These results
confirmed the diagnosis of 17OHD.
After the first month of treatment with dexa-
methasone (1 mg/day), systolic blood pressure was
reduced from 161 mmHg to 139 mmHg, and po-
tassium (3.4 mmol/dL), aldosterone (136 pg/mL)
and ACTH (16 pg/mL) returned to within normal
limits. Nevertheless, the patient was very concerned
about the side effect of body weight gain with
glucocorticoid therapy, so the dose was tapered
(0.5 mg/day) from the second month of treatment.
Potassium and aldosterone levels remained with-
in normal levels but hypertension rebounded.
Therefore, spironolactone (25 mg, QD) was add-
ed to the regimen from the third month. Systolic
blood pressure decreased to 130–140 mmHg in
the following months. During treatment, plasma
ACTH and aldosterone were elevated (77.1 pg/mL
and 264 pg/mL, respectively) due to poor drug
compliance (Table). Estrogen replacement thera-
py to induce pubertal development was started
soon after the clinical diagnosis of 17OHD. Her
initial predicted adult height (by the Bayley and
Pinneau method) was 208.3 cm, and bone age was
measured according to the Greulich-Pyle method.
Therefore, sex hormone replacement was increased
rapidly for the purpose of reducing the predicted
adult height and final height. Her last predicted
adult height was 176.5 cm after hormone replace-
ment therapy for 9 months.
Discussion
The classical presentation of 17OHD is hyperten-
sion, hypokalemia and lack of secondary sexu-
al development;2 all of these features were found
in our patient. Affected genetic males usually pre-
Figure. Direct genomic DNA sequence analysis of exon 2 and exon 8 of CYP17 in
the index patient. The 9-bp (GACTCTTTC) deletion from nucleotide position
1519 of exon 8 and 376T>C (S106P) mutation of exon 2.
sent with a complete female phenotypic appear-
ance or, less often, with ambiguous external
genitalia.3,7 The magnitude of impaired masculi-
nization in the male fetus correlates with enzy-
matic activity of the severity of the block in 17_-
hydroxylation and the degree of the subsequent
defect in fetal testosterone synthesis. Analysis
of enzymatic activity has shown that more than
25% of normal activity is necessary for normal
fetal masculinization of the external genitalia.1,7
The clinical presentation of our patient was con-
sidered severe due to the completely female phe-
notype, although enzyme activity tests were not
available in our country at the time of treatment.
In 17OHD, decreased cortisol secretion causes
increased ACTH production, which results in
overproduction of 17-deoxysteroids by the ad-
renal cortex, including DOC, corticosterone and
18-hydroxycorticosterone. However, data on 17-
deoxysteroids were not obtained in our patient
due to lack of availability of these tests in our
country. Serum progesterone, which is one of
the 17_-hydroxylase substrates and is a useful
marker in the diagnosis of 17OHD,11 was elevated
in our patient. After ACTH stimulation test, the
level of progesterone changed little, from 8.5
ng/mL to 8.7 ng/mL. The final diagnosis was con-
firmed by CYP17 genotyping.
Most patients with 17OHD have very low or
subnormal production of aldosterone.7,12 It has
been suggested that the inhibition of aldosterone
biosynthesis is mediated by the increased levels
of DOC, which leads to suppression of the renin-
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angiotensin system via an increased reabsorp-
tion of sodium and increased blood volume.13 In
contrast, serum aldosterone was elevated in this
patient. Several other studies reported similar
findings, especially in Japanese patients (16/20
cases).7,12,14 Yamakita et al speculated that the
more severe the deficiency of 17_-hydroxylase
activity, the more active is the corticosterone me-
thyl oxidase in fasciculata cells, resulting in great-
er production of aldosterone from corticosterone.
Patients with severe deficiency of 17_-hydroxylase
activity may fall into a broad category of glucocor-
ticoid-remediable hyperaldosteronism.9 17OHD
with glucocorticoid-remediable hyperaldosteron-
ism, as well as elevated aldosterone levels that
increased following ACTH stimulation and which
responded to steroid replacement, has been
reported.14 Since our patient had no family history
of hypertension, particularly in her parents, and
neither her aldosterone level (from 317 pg/dL to
333 pg/dL) nor cortisol level (from 1.77 +g/dL to
2.59 +g/dL) were significantly responsive after
1-hour ACTH stimulation test, glucocorticoid-
remediable aldosteronism was considered unlikely.
The renin-angiotensin-aldosterone axis is inde-
pendent from the hypothalamus-pituitary-adrenal
axis, and its regulation and interactions are very
complicated. Therefore, the mechanism of low nor-
mal renin level in this case remains to be clarified.
Usually, hypertension resolves with glucocor-
ticoid therapy,15 but it may persist if the diagnosis
is delayed.16 Mineralocorticoid antagonists such as
spironolactone or potassium canrenoate can be
added to the regimen to achieve better control of
blood pressure.16 The addition of a calcium chan-
nel blocker to the regimen is usually effective if
hypertension persists despite adequate blockade
of mineralocorticoid production and action.12,16
Female sex assignment was continued in this
chromosomally male patient due to established
psychosexual development and identity. Estrogen
replacement therapy was given for induction of
female secondary sex characteristics. This therapy
may also reduce final height.17
Prophylactic gonadectomy should be per-
formed in genetic males with 17OHD because of
the risk of malignant change. The testes may be
intra-abdominal, in the inguinal canal, or in the
labioscrotal folds.1 As this patient was depressed
and suicidal due to lack of sexual development,
removal of gonads was postponed.
Nearly 50 different mutations in CYP178 have
been reported since 1988.18 Most of the mutations
appear to be random, except for one reported in
Canadian Mennonite descendants of Dutch Fries-
landers.7 In our patient, the compound hetero-
zygous mutations, including a 9-bp (GACTCTTTC)
deletion in exon 8 and S106P mutation in exon 2,
were identified as inherited from the father and
mother, respectively. Both of these mutations have
been previously described in two unrelated Gua-
manian patients and a patient from Thailand, as
well as in two siblings from China.19–21
In conclusion, 17OHD is a rare condition which
has not been previously reported in Taiwan. It
should be suspected in patients with hypokalemic
hypertension and lack of secondary sexual devel-
opment so that appropriate therapy can be im-
plemented.
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